---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455339"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2026-11-10T20:50:16+00:00"
generated_at: "2026-11-10T20:51:04.430589+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exicure to sell GPC-100 (burixafor) assets to Korea's GPCRT for KRW 6.5B (~US$4.8M)

## Summary
- Aggregate cash price KRW 6.5B (~US$4.8M): KRW 500M deposit already paid and credited, KRW 2.0B due by November 16, 2026, KRW 4.0B at closing.
- Assets: rights under the January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, plus IP, clinical/regulatory data, materials and equipment.
- GPCRT assumes post-closing obligations including future milestone and royalty payments to GPCR, and bears GPC-100 program costs incurred on or after September 1, 2026.
- GPC-100 was evaluated with propranolol for stem cell mobilization in multiple myeloma; GPCR USA completed its Phase 2 trial in January 2026.
- Closing needs board approvals, regulatory and third-party consents, a GPCR waiver/release, and any required Exicure stockholder approval; timing not assured.

## SEC filing metadata
- accession: 0001193125-26-455339
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2026-11-10T20:50:16+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000119312526455339/0001193125-26-455339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000119312526455339/xcur-20261104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455339
- JSON: https://secwatch.observer/filing/0001193125-26-455339.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.